Biotech giant Biogen (NASDAQ: BIIB) was underperforming the market this year -- that is, until the company's shares soared by as much as 37% last week. The drugmaker's major win in the stock market came after it reported positive top-line results from a phase 3 clinical trial for lecanemab, a potential therapy for Alzheimer's disease (AD).

Biogen is developing lecanemab in collaboration with Japan-based Esai. Why were these results such a big deal for Biogen? And is it a good idea to follow the crowd and purchase shares following these recent developments?

Continue reading

Source Fool.com